Polymotion IDE Study Passes 60% Enrolment

The Polymotion® Hip Resurfacing (PHR®) IDE study has officially passed the 60% enrolment mark, bringing us another step closer to completing this pivotal trial. This achievement underscores the accelerating pace of patient recruitment and the strong interest in next-generation hip resurfacing within the U.S.

As part of this momentum, we have welcomed our final clinical site into the programme:

• Dr. David Scott – Orthopaedic Speciality Clinic (Spokane, WA)

  
  

With this addition, the study network now spans across ten leading hip arthroplasty centres, a reflection of the growing confidence surgeons and patients have in the Polymotion® system.

The Polymotion® Hip Resurfacing System is an investigational device designed for active patients seeking bone-conserving alternatives to traditional hip replacement. Unlike contemporary metal-on-metal technologies, the Polymotion® system combines a Vitamin E-infused polyethylene cup with a titanium-coated shell and a metal femoral cap — avoiding metal-on-metal articulation while maintaining excellent range of motion and implant stability.

The IDE study is currently active at the following clinical sites:

• Mr. Ronan Treacy and Dr. Will Peckett – King Edward VII (Bermuda)

• Dr. Thomas Gross and Dr. Coleman Fowble – Midlands Orthopaedics & Neurosurgery (Columbia, SC)

• Dr. Stephen Raterman – Florida Medical Clinic Orlando Health (Tampa, FL)

• Dr. William Macaulay, Dr. Scott Marwin, and Dr. Matthew Hepinstall – NYU Langone (New York, NY)

• Dr. Craig Della Valle – Rush University Medical Center (Chicago, IL)

• Dr. Michael Mont – Sinai Hospital (Baltimore, MD)

• Dr. Ronald Delanois – Formerly of Sinai Hospital (Baltimore, MD)

• Dr. Anthony Carter – Hampton Roads Orthopaedics (Newport News, VA)

• Dr. Thomas Huff – Oregon Health & Science University (Portland, OR)

• Dr. David Crawford – Joint Implant Surgeons (New Albany, OH)

• Dr. David Scott – Orthopaedic Speciality Clinic (Spokane, WA)

We are thankful to our investigators and partners whose commitment is helping us reach full enrolment.

The high rate of participation reflects the demand for alternative resurfacing solutions that avoid the risks of metal-on-metal bearings. This is especially meaningful for younger, active patients, including women and smaller-framed individuals, who have often had limited access to resurfacing options in the past.

JointMedica’ s Chief Commercial Officer Tim Band stated ““Reaching 60% enrolment is a clear signal of both surgeon support and patient demand. The enthusiasm we’re seeing across leading orthopaedic centres gives us confidence that the Polymotion® system can address a real gap in care. We are grateful to every surgeon and every patient who is making this study possible.”

With recruitment continuing to move at pace, we are optimistic about reaching full enrolment and look forward to sharing further progress soon.